JPWO2020006631A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020006631A5
JPWO2020006631A5 JP2021512244A JP2021512244A JPWO2020006631A5 JP WO2020006631 A5 JPWO2020006631 A5 JP WO2020006631A5 JP 2021512244 A JP2021512244 A JP 2021512244A JP 2021512244 A JP2021512244 A JP 2021512244A JP WO2020006631 A5 JPWO2020006631 A5 JP WO2020006631A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
repyrinast
subject
alcoholic steatohepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021512244A
Other languages
English (en)
Japanese (ja)
Other versions
JP7399949B2 (ja
JP2021535175A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2019/050915 external-priority patent/WO2020006631A1/en
Publication of JP2021535175A publication Critical patent/JP2021535175A/ja
Publication of JPWO2020006631A5 publication Critical patent/JPWO2020006631A5/ja
Application granted granted Critical
Publication of JP7399949B2 publication Critical patent/JP7399949B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021512244A 2018-07-06 2019-07-03 非アルコール性脂肪性肝炎治療のための組成物及び方法 Active JP7399949B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862694848P 2018-07-06 2018-07-06
US62/694,848 2018-07-06
US201962809351P 2019-02-22 2019-02-22
US62/809,351 2019-02-22
PCT/CA2019/050915 WO2020006631A1 (en) 2018-07-06 2019-07-03 Compositions and methods for treating non-alcoholic steatohepatitis

Publications (3)

Publication Number Publication Date
JP2021535175A JP2021535175A (ja) 2021-12-16
JPWO2020006631A5 true JPWO2020006631A5 (enExample) 2022-07-12
JP7399949B2 JP7399949B2 (ja) 2023-12-18

Family

ID=69060680

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021512244A Active JP7399949B2 (ja) 2018-07-06 2019-07-03 非アルコール性脂肪性肝炎治療のための組成物及び方法

Country Status (6)

Country Link
US (1) US11744808B2 (enExample)
EP (2) EP4541352A3 (enExample)
JP (1) JP7399949B2 (enExample)
CN (1) CN112654357B (enExample)
CA (1) CA3105850A1 (enExample)
WO (1) WO2020006631A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020191503A1 (en) * 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Methods and uses of bromantane and derivatives thereof for treating lung disease, fatty liver disease, and kidney disorders
WO2020191501A1 (en) * 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Methods and uses of bemithyl and derivatives for treating lung disease, fatty liver disease, and kidney disorders
IT202100014177A1 (it) * 2021-05-31 2022-12-01 Sunnutrapharma S R L Utilizzo della istradefillina per ridurre la fibrosi d’organo
CN115778957B (zh) * 2022-11-04 2024-06-21 天津中医药大学 千金藤素及包含其的组合物用于预防或治疗酒精性肝病的应用
CN120346213B (zh) * 2025-05-13 2025-10-24 中国医科大学 CD39抑制剂或A2a受体抑制剂在制备治疗非酒精性脂肪肝炎产品中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2175229C2 (ru) * 1999-12-22 2001-10-27 Научно-исследовательский институт фармакологии РАМН Анксиолитическое средство
JP3885135B2 (ja) * 2000-10-10 2007-02-21 幸彦 松田 Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤
RU2261709C2 (ru) * 2003-08-15 2005-10-10 Государственное учреждение Научно-исследовательский институт фармакологии Российской Академии медицинских наук Психостимулирующее средство
WO2008119988A1 (en) * 2007-03-30 2008-10-09 Cardoz Ab New combination for use in the treatment of inflammatory disorders
WO2009007679A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist
WO2012157290A1 (ja) * 2011-05-19 2012-11-22 富士化学工業株式会社 非アルコール性脂肪性肝炎の予防改善剤
EP2818473A4 (en) * 2012-02-20 2015-04-15 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
RU2547141C1 (ru) * 2014-02-28 2015-04-10 Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) Способ получения n-(4-бромфенил)-n-(2-адамантил)амина (бромантана)
WO2017100500A1 (en) * 2015-12-11 2017-06-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vesicle containing metallic nanoparticle and method for production thereof

Similar Documents

Publication Publication Date Title
JP2024028337A5 (enExample)
JP2006104221A5 (enExample)
CN111868056A (zh) 1,2,4-噁二唑类化合物及其制备方法和医药用途
MY144043A (en) A pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases
NZ597830A (en) Methods and compositions for treating cancer comprising abiraterone acetate and prednisone
JP2008505857A5 (enExample)
JP2005503399A5 (enExample)
JP2016530279A5 (enExample)
JP2020111586A5 (enExample)
JPWO2020006631A5 (enExample)
JP2009541409A5 (enExample)
WO2024165571A3 (en) Inhibitors of expression and/or function
JP2018505218A5 (enExample)
JP2008533021A5 (enExample)
WO2007121545A8 (en) S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
JP2009505991A5 (enExample)
JP2022033803A5 (enExample)
JP2007514699A5 (enExample)
JP2009502937A5 (enExample)
JPWO2020000092A5 (enExample)
WO2007036809A3 (en) Novel acetylsalicylic acid formulations
Levy Fibrates for primary biliary cholangitis: what’s all the hype?
WO2009041798A8 (es) Composiciones farmacéuticas que comprenden la combinación de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa útiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas.
JP2023078477A5 (enExample)
JP2016539149A5 (enExample)